Epkinly FDA Approved for Treatment of Advanced Diffuse Large B-Cell Lymphoma.
- Published in:
- Oncology Practice Management, 2023, v. 13, n. 7, p. 21
- Publication type:
- Article
Works matching IS 21644403 AND DT 2023 AND VI 13 AND IP 7
Results: 9
1
2
FDA Approves Columvi for Select Patients With Relapsed or Refractory Large B-Cell Lymphomas.
- Published in:
- Oncology Practice Management, 2023, v. 13, n. 7, p. 21
- Publication type:
- Article
3
Nurse-Led Survivorship Care Programs May Improve the Health and Resilience of Primary Caregivers of Patients With Cancer.
- Published in:
- Oncology Practice Management, 2023, v. 13, n. 7, p. 20
- Publication type:
- Article
4
Ribociclib Plus Adjuvant Endocrine Therapy Reduces Risk for Recurrence in HR-Positive, HER2-Negative, Early Breast Cancer.
- Published in:
- Oncology Practice Management, 2023, v. 13, n. 7, p. 12
- By:
- Publication type:
- Article
5
Emerging Therapeutic Targets for CCA From Translational Research.
- Published in:
- Oncology Practice Management, 2023, v. 13, n. 7, p. 10
- Publication type:
- Article
6
SARC Launches National Virtual Multidisciplinary Tumor Board for Sarcoma, Representing Nearly 20% of Childhood Cancers and 1% of Adult Cancers.
- Published in:
- Oncology Practice Management, 2023, v. 13, n. 7, p. 6
- Publication type:
- Article
7
July Is Sarcoma and Bone Cancer Awareness Month.
- Published in:
- Oncology Practice Management, 2023, v. 13, n. 7, p. 1
- Publication type:
- Article
8
Physician Debate: Is Chemotherapy Still the Backbone for CCA Treatment?
- Published in:
- Oncology Practice Management, 2023, v. 13, n. 7, p. 1
- Publication type:
- Article
9
Partnering With Patients to Improve Healthcare Outcomes.
- Published in:
- Oncology Practice Management, 2023, v. 13, n. 7, p. 1
- By:
- Publication type:
- Article